Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

F0260000

Fluphenazine decanoate

European Pharmacopoeia (EP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C32H44F3N3O2S
Numéro CAS:
5002-47-1
Poids moléculaire :
591.77
Numéro CE :
225-672-4
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluphenazine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Clé InChI

VIQCGTZFEYDQMR-UHFFFAOYSA-N

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000009

Fluphenazine enantate, European Pharmacopoeia (EP) Reference Standard

Y0000298

Fluphenazine octanoate, European Pharmacopoeia (EP) Reference Standard

Y0000299

Fluphenazine sulfoxide, European Pharmacopoeia (EP) Reference Standard

Y0000708

Fluphenazine impurity mixture, European Pharmacopoeia (EP) Reference Standard

F0280000

Fluphenazine dihydrochloride, European Pharmacopoeia (EP) Reference Standard

1282004

Fluphenazine hydrochloride, United States Pharmacopeia (USP) Reference Standard

1280803

Fluphenazine decanoate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

1281001

Fluphenazine enanthate dihydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1792

Fluphenazine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP167

Fluphenazine hydrochloride, British Pharmacopoeia (BP) Reference Standard

1282026

Fluphenazine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H300,H361

Classification des risques

Acute Tox. 2 Oral - Repr. 2

Code de la classe de stockage

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Who receives long-acting antipsychotic medications?
William M Glazer
Psychiatric services (Washington, D.C.), 58(4), 437-437 (2007-04-07)
Branimir Margetić et al.
Psychiatria Danubina, 17(1-2), 94-96 (2006-01-07)
We describe the case of a 39-year-old patient with schizophrenia who developed worsening of glucose metabolism during treatment with two different atypical antipsychotics, clozapine and quetiapine. Diabetes mellitus was recognized during clozapine treatment. During quetiapine treatment, while patient was taking
Zana Stanković et al.
Psychiatria Danubina, 20(1), 42-52 (2008-04-01)
To compare patient's attitudes, demographic, clinical characteristics, psychopathology, insight and type of antipsychotic therapy in compliant and non-compliant outpatients with schizophrenia; to explore correlations between patient's attitudes and related variables. A sample of 44 outpatients of both genders (> 60
Martin Turner et al.
International clinical psychopharmacology, 19(4), 241-249 (2004-06-18)
Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or
Janice Charles et al.
Australian family physician, 35(3), 88-89 (2006-03-10)
The BEACH program, a continuous national study of general practice activity in Australia, gives us an overview of consultations involving the management of psychoses. In this analysis we have included schizophrenia, affective disorders/bipolar, organic psychoses, and senile psychoses, with undefined
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique